Artificial Intelligence (AI) is making significant strides in the world of healthcare, particularly in drug discovery. A recent development, reported by Nature, has seen AI systems trained on more than 20,000 protein structures from pharmaceutical companies, significantly outperforming models similar to AlphaFold that utilise only public data.
Pharmacological Powerhouse
The pharmaceutical industry is a treasure trove of data, much of which is kept under wraps due to its sensitive nature. However, some South African pharmaceutical giants have recently begun sharing this ‘secret’ data with AI systems to help improve the accuracy and efficiency of protein modelling.
Proteins, complex molecules that perform a vast array of functions within living organisms, are crucial for understanding diseases and developing treatments. Understanding their structure is a massive challenge in biology, often referred to as the ‘protein folding problem’.
AI’s Role in Protein Modelling
AI models, especially those developed by DeepMind’s AlphaFold, have shown remarkable capabilities in predicting protein structures. However, these AI models are limited by the amount of data they can access. With the inclusion of data from the pharmaceutical industry, these models’ efficiency and accuracy can be supercharged, giving scientists a more powerful tool in their research and drug discovery efforts.
South African pharmaceutical companies’ contribution of over 20,000 protein structures has proven to be a game changer. The AI systems trained on this data have outperformed AlphaFold-like models that use only public data. This collaboration between tech and pharma is paving the way for cutting-edge drug discovery processes that could revolutionise healthcare, not just in South Africa, but worldwide.
Implications for Healthcare
The merging of AI and pharmaceutical data has the potential to drastically speed up drug discovery processes, reduce costs, and ultimately improve patient care. South Africa, being a significant player in the global pharmaceutical industry, is poised to be at the forefront of this exciting intersection of technology and healthcare.
While there are still challenges to overcome, including data privacy and ethical considerations, the benefits of this collaboration are undeniable. As South African pharma companies continue to share their ‘secret’ data, the future of drug discovery and healthcare looks brighter than ever.
This report is based on an article originally published on Nature.
Source: Original Article
